Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1782303rdf:typepubmed:Citationlld:pubmed
pubmed-article:1782303lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:1782303lifeskim:mentionsumls-concept:C0021853lld:lifeskim
pubmed-article:1782303lifeskim:mentionsumls-concept:C0003211lld:lifeskim
pubmed-article:1782303lifeskim:mentionsumls-concept:C0038792lld:lifeskim
pubmed-article:1782303lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:1782303lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:1782303lifeskim:mentionsumls-concept:C1524063lld:lifeskim
pubmed-article:1782303lifeskim:mentionsumls-concept:C0439858lld:lifeskim
pubmed-article:1782303lifeskim:mentionsumls-concept:C1883709lld:lifeskim
pubmed-article:1782303pubmed:issue6lld:pubmed
pubmed-article:1782303pubmed:dateCreated1992-3-18lld:pubmed
pubmed-article:1782303pubmed:abstractTextTo test the hypothesis that administration of a non-steroidal anti-inflammatory drug formulated as a pro-drug, inactive as a cyclooxygenase inhibitor until after absorption, might cause less intestinal damage than conventional non-steroidal anti-inflammatory drugs, intestinal permeation to 51Cr-EDTA and mannitol was assessed in healthy volunteers before and after oral treatment for 1 week with either the pro-drug sulindac or the conventional non-steroidal anti-inflammatory drug indomethacin. Indomethacin, but not sulindac, significantly increased intestinal permeation to 51Cr-EDTA and reduced haemoglobin and haematocrit; neither affect mannitol permeation.lld:pubmed
pubmed-article:1782303pubmed:languageenglld:pubmed
pubmed-article:1782303pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1782303pubmed:citationSubsetIMlld:pubmed
pubmed-article:1782303pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1782303pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1782303pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1782303pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1782303pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1782303pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1782303pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1782303pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1782303pubmed:statusMEDLINElld:pubmed
pubmed-article:1782303pubmed:monthDeclld:pubmed
pubmed-article:1782303pubmed:issn0269-2813lld:pubmed
pubmed-article:1782303pubmed:authorpubmed-author:RamptonD SDSlld:pubmed
pubmed-article:1782303pubmed:authorpubmed-author:DaviesG RGRlld:pubmed
pubmed-article:1782303pubmed:issnTypePrintlld:pubmed
pubmed-article:1782303pubmed:volume5lld:pubmed
pubmed-article:1782303pubmed:ownerNLMlld:pubmed
pubmed-article:1782303pubmed:authorsCompleteYlld:pubmed
pubmed-article:1782303pubmed:pagination593-8lld:pubmed
pubmed-article:1782303pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1782303pubmed:meshHeadingpubmed-meshheading:1782303-...lld:pubmed
pubmed-article:1782303pubmed:meshHeadingpubmed-meshheading:1782303-...lld:pubmed
pubmed-article:1782303pubmed:meshHeadingpubmed-meshheading:1782303-...lld:pubmed
pubmed-article:1782303pubmed:meshHeadingpubmed-meshheading:1782303-...lld:pubmed
pubmed-article:1782303pubmed:meshHeadingpubmed-meshheading:1782303-...lld:pubmed
pubmed-article:1782303pubmed:meshHeadingpubmed-meshheading:1782303-...lld:pubmed
pubmed-article:1782303pubmed:meshHeadingpubmed-meshheading:1782303-...lld:pubmed
pubmed-article:1782303pubmed:meshHeadingpubmed-meshheading:1782303-...lld:pubmed
pubmed-article:1782303pubmed:meshHeadingpubmed-meshheading:1782303-...lld:pubmed
pubmed-article:1782303pubmed:meshHeadingpubmed-meshheading:1782303-...lld:pubmed
pubmed-article:1782303pubmed:meshHeadingpubmed-meshheading:1782303-...lld:pubmed
pubmed-article:1782303pubmed:meshHeadingpubmed-meshheading:1782303-...lld:pubmed
pubmed-article:1782303pubmed:meshHeadingpubmed-meshheading:1782303-...lld:pubmed
pubmed-article:1782303pubmed:meshHeadingpubmed-meshheading:1782303-...lld:pubmed
pubmed-article:1782303pubmed:year1991lld:pubmed
pubmed-article:1782303pubmed:articleTitleThe pro-drug sulindac may reduce the risk of intestinal damage associated with the use of conventional non-steroidal anti-inflammatory drugs.lld:pubmed
pubmed-article:1782303pubmed:affiliationGastrointestinal Science Research Unit, London Hospital Medical College, UK.lld:pubmed
pubmed-article:1782303pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1782303pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:1782303pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1782303lld:pubmed